Methoxy Polyethylene Glycol-Epoetin Beta (Mircera®) Injection

Mircera is covered for anemia of chronic kidney disease in adults (on dialysis or not) and only for pediatric patients 5–17 years who are converting from another ESA while on hemodialysis; non‑FDA uses are excluded. Coverage requires documentation of age and dialysis status, adequate iron stores or current iron therapy, hemoglobin <10.0 g/dL for initial starts (or <11.5 g/dL for those already on an ESA), adherence to specified dosing/routes (adult SC or IV; pediatric IV) and prior‑ESA hemoglobin stabilization for pediatric converters, with authorizations limited to 12 months.

"Mircera is indicated for the treatment of anemia associated with chronic kidney disease in adult patients on dialysis and adult patients not on dialysis"

Sign up to see full coverage criteria, indications, and limitations.